Navigation Links
Isis Pharmaceuticals to Present at the 2012 Citi Global Health Care Conference
Date:2/21/2012

CARLSBAD, Calif., Feb. 21, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Citi's 2012 Global Health Care Conference on Tuesday, February 28, 2012 at 2:00 p.m. ET at the Waldorf Astoria in New York City.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 ... ), a developer of a new generation of ... positive overall survival results for Paclical/Apealea in the ... 789 patients with epithelial ovarian cancer. These preliminary ... Paclical/Apealea in combination with carboplatin versus Taxol in ...
(Date:4/27/2016)... April 27, 2016 At the ... launch of a Phase 2 clinical study of its ... patients undergoing cochlear implantation (CI) surgery. This large, placebo-controlled, ... Germany and France ... ear at the time of surgery. "Despite advances in ...
(Date:4/26/2016)... CLEVELAND , April 26, 2016 ... is forecast to expand 4.9 percent annually to ... and other healthcare facilities to decrease rates of ... infection prevention supplies, equipment, and services.  Although declining, ... is significantly above targeted levels set by the ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... 28, 2016 , ... Greener Hydroponics is now offering a large selection of ... professional organic farmers and nurseries according to Sales Manager Joe Steele who says, “Now ... goal is to offer wholesale level pricing and ultra-fast shipping for growers of any ...
(Date:4/28/2016)... ... April 28, 2016 , ... In 2011, TIME magazine named Herr ... field of biomechatronics, technology that marries human physiology with electromechanics. He continues that work ... also the Founder of BionX , a leader in the field of prosthetic ...
(Date:4/28/2016)... (PRWEB) , ... April 28, ... ... leading provider of enterprise Data Center Infrastructure Management solutions, announces today the ... on feature enhancements in the area of capacity management and optimization, providing ...
(Date:4/28/2016)... , ... April 28, 2016 , ... One way to ... anything.” This is unfortunately true. But we toss the baby out with the bathwater ... brief provides tips for identifying higher-quality studies and otherwise making better use of education ...
(Date:4/28/2016)... , ... April 28, 2016 , ... USA Medical Card reminds us that May is ... a stroke is the fourth leading cause of death in the United States; someone has ... a quarter of them in individuals under 65 years old. A stroke is when ...
Breaking Medicine News(10 mins):